61.22
-2.63 (-4.12%)
| Previous Close | 63.85 |
| Open | 63.65 |
| Volume | 2,253,926 |
| Avg. Volume (3M) | 1,384,448 |
| Market Cap | 8,087,774,208 |
| Price / Earnings (TTM) | 23.73 |
| Price / Earnings (Forward) | 13.00 |
| Price / Sales | 8.07 |
| Price / Book | 23.56 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2024 - 8 Nov 2024 |
| Profit Margin | 38.62% |
| Operating Margin (TTM) | 50.67% |
| Diluted EPS (TTM) | 2.58 |
| Quarterly Revenue Growth (YOY) | 4.70% |
| Quarterly Earnings Growth (YOY) | 24.70% |
| Total Debt/Equity (MRQ) | 529.73% |
| Current Ratio (MRQ) | 7.41 |
| Operating Cash Flow (TTM) | 419.99 M |
| Levered Free Cash Flow (TTM) | 335.21 M |
| Return on Assets (TTM) | 13.38% |
| Return on Equity (TTM) | 153.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Halozyme Therapeutics, Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.80 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 98.94% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (HC Wainwright & Co., 6.17%) | Buy |
| Median | 60.00 (-1.99%) | |
| Low | 49.00 (Goldman Sachs, -19.96%) | Hold |
| Average | 58.60 (-4.28%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 56.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 07 Oct 2024 | 62.00 (1.27%) | Hold | 53.85 |
| HC Wainwright & Co. | 04 Oct 2024 | 65.00 (6.17%) | Buy | 59.18 |
| 16 Sep 2024 | 65.00 (6.17%) | Buy | 62.91 | |
| JP Morgan | 19 Sep 2024 | 57.00 (-6.89%) | Hold | 59.50 |
| Benchmark | 08 Aug 2024 | 60.00 (-1.99%) | Buy | 54.46 |
| Goldman Sachs | 22 Jul 2024 | 49.00 (-19.96%) | Hold | 54.34 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TORLEY HELEN | - | 52.40 | -20,000 | -1,047,900 |
| Aggregate Net Quantity | -20,000 | |||
| Aggregate Net Value ($) | -1,047,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 52.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 09 Oct 2024 | Automatic sell (-) | 10,000 | 50.66 | 506,600 |
| TORLEY HELEN | Officer | 09 Oct 2024 | Option execute | 10,000 | - | - |
| TORLEY HELEN | Officer | 08 Oct 2024 | Automatic sell (-) | 10,000 | 54.13 | 541,300 |
| TORLEY HELEN | Officer | 08 Oct 2024 | Option execute | 10,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Oct 2024 | Announcement | Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE® |
| 13 Sep 2024 | Announcement | Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis |
| 12 Sep 2024 | Announcement | Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer |
| 28 Aug 2024 | Announcement | Halozyme to Present at Upcoming Investor Conferences |
| 06 Aug 2024 | Announcement | HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS |
| 23 Jul 2024 | Announcement | Halozyme to Report Second Quarter 2024 Financial and Operating Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |